Copeptin as a diagnostic PH marker in acute pulmonary embolism
Copeptin as a diagnostic PH marker in acute pulmonary embolism
Objective: The present study aimed to investigate the effectiveness of copeptin levels in detecting increased pulmonary artery pressure and right ventricular dysfunction in patients with acute pulmonary embolism.
Methods: A total of 116 patients who presented to the emergency department with chest pain or dyspnea and were diagnosed with acute pulmonary embolism and 30 healthy controls were included in the study. Plasma copeptin levels of patients and healthy control group were measured. Right ventricular functions and pulmonary artery pressures were evaluated in echocardiography of patients diagnosed with acute
pulmonary embolism.
Results: Copeptin levels were significantly higher in patients with right ventricular dysfunction than in those without right ventricular dysfunction [median 1.06(0.03–7.14) vs. 0.59(0.31–2.50), p= 0.01].
Conclusion: Copeptin can be used as a new biomarker in the diagnosis of acute pulmonary embolism and in predicting right ventricular dysfunction and increased pulmonary artery pressure in patients with acute pulmonary embolism
___
- [1] İpekci A. Pulmonary Embolism. Phnx Med J 2019;1(1):51-63.
- [2] Ozturk N, Baygutalp NK, Bayramoglu A, Polat H, Gul MA, Bakan
E, Aslan S, Gunes ON. The evaluation of serum copeptin levels
and some commonly seen thrombophilic mutation prevalence
in acute pulmonary embolism. Biochemical Genetics
2016;54(3):306-312.
- [3] Kalkan AK, Ozturk D, Erturk M, Kalkan ME, Cakmak HA, Oner
E, Uzun F, Tasbulak O, Yakisan T, Celik A. The diagnostic value
of serum copeptin levels in an acute pulmonary embolism.
Cardiology Journal 2016;23(1):42-50.
- [4] Volpi S, Rabadan-Diehl C, Aguilera G. Vasopressinergic
regulation of the hypothalamic pituitary adrenal axis and
stress adaptation. Stress 2004;7:75–83.
- [5] Bolignano D, Cabassi A, Fiaccadori E, Ghigo E, Pasquali R,
Peracino A, Peri A, Plebani M, Santoro A, Settanni F, Zoccali
C. Copeptin (CTproAVP), a new tool for understanding the
role of vasopressin in pathophysiology. Clin Chem Lab Med
2014;52(10):1447–1456.
- [6] Katan M, Christ-Crain M. The stress hormone copeptin: a
new prognostic biomarker in acute illness. Swiss Med Wkly
2010;140(24):11–15.
- [7] Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller
B, Christ-Crain M. Copeptin, a stable peptide derived from the
vasopressin precursor, correlates with the individual stress
level. Neuro Endocrinol Lett 2008;29:341–346.
- [8] Wyzgał A, Koc M, Pacho S, Bielecki M, Wawrzyniak R,
Kostrubiec M, Ciurzynski M, Kurnicka K, Goliszek S, Paczynska
M, Palczewski P, Pruszczyk P. Plasma copeptin for short term
risk stratification in acute pulmonary embolism. Journal of
Thrombosis and Thrombolysis 2016;41(4):563-568.
- [9] Nickel NP, Lichtinghagen R, Golpon H, Olsson KM, Brand K,
Welte T, Hoeper MM. Circulating levels of copeptin predict
outcome in patients with pulmonary arterial hypertension.
Respiratory Research 2013;14(1):130.
- [10] Vuilleumier N, Simona A, Méan M, Limacher A, Lescuyer P,
Gerstel E, Bounameaux H, Aujesky D, Righini M. Comparison
of cardiac and non-cardiac biomarkers for risk stratification in
elderly patients with non-massive pulmonary embolism. PloS
One 2016;11(5).
- [11] Khan SQ, Dhillon OS, O’Brien RJ, StruckJ, Quinn PA,
Morgenthaler NG, Squire IB, Davies JE, Bergmann
A, Ng LL. C-terminal provasopressin (copeptin) as a
novelandprognostic marker in acutemyocardialinfarction:
LeicesterAcuteMyocardialInfarctionPeptide (LAMP) study.
Circulation 2007;115:21.
- [12] Treschan TA, Peters J. The vasopressin system: Physiology and
clinical strategies. Anesthesiology 2006;105:599–612.
- [13] Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for
the measurement of copeptin, a stable peptide derived from
the precursor of vasopressin. Clin Chem 2006;52:112–119.
- [14] Timuralp B. Pulmoner tromboembolide kardiyovasküler
sistemde gelişen patofizyolojik değişiklikler. Metintaş M
(editör). Pulmoner Tromboemboli. ASD Toraks yayınları, Metin
Ofset Matbaacılık, Eskişehir 2001:73-83. (Turkish)
- [15] Coşkun B, Kırkıl G, Hamdi M, Yıldız M, Özbay Y. Submasif
pulmoner tromboemboli olgularında sağ ventrikül
disfonksiyonunu saptamada beyin natriüretik peptid
ve kardiyak troponin I’nın tanı değeri. Turk Toraks Derg
2012;13:163-168. (Turkish)
- [16] Goldhaber SZ. Cardiac biomarkers in pulmonary embolism.
Chest 2003;123:82-84.
- [17] Goldsmith SR, Gheorghiade M. Vasopressin antagonism in
heart failure. J Am Coll Cardiol. 2005;46:1785–1791.
- [18] Deveci F, Öner Ö, Telo S, Kırkıl G, Balin M, Kuluöztürk M.
Prognostic value of copeptin in patients with acute pulmonary
thromboembolism. The Clinical Respiratory Journal
2019;13(10):630-636.
- [19] Laporte S, Mismetti P, Décousus H, Uresandi F, Otero R, Lobo JL,
Monreal M. Clinical predictors for fatal pulmonary embolism
in 15,520 patients with venous thromboembolism: findings
from the Registro Informatizado de la Enfermedad Trombo
Embolica venosa (RIETE) registry. Circulation 2008;117:1711–
1716.
- [20] Aujesky D, Jiménez D, Mor MK, Geng M, Fine MJ, Ibrahim SA.
Weekend versus week day admission and mortality afteracu
tepulmonary embolism. Circulation 2009;119:962–968